Loading…

Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis

In this study, the effect of 15-month anti-tumor necrosis factor alpha (TNF-α) treatment on circulating levels of plasma sulfated glycosaminoglycans (GAGs) and the nonsulfated GAG hyaluronic acid (HA) in female rheumatoid arthritis (RA) patients was assessed. Plasma was obtained from healthy subject...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis research & therapy 2018-09, Vol.20 (1), p.211-211, Article 211
Main Authors: Szeremeta, Anna, Jura-Półtorak, Agnieszka, Koźma, Ewa Maria, Głowacki, Andrzej, Kucharz, Eugeniusz Józef, Kopeć-Mędrek, Magdalena, Olczyk, Krystyna
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c493t-4c9965f93d2627fc2479c7441f5d75868083655f674ea7dd960b2d9aa50f35423
cites cdi_FETCH-LOGICAL-c493t-4c9965f93d2627fc2479c7441f5d75868083655f674ea7dd960b2d9aa50f35423
container_end_page 211
container_issue 1
container_start_page 211
container_title Arthritis research & therapy
container_volume 20
creator Szeremeta, Anna
Jura-Półtorak, Agnieszka
Koźma, Ewa Maria
Głowacki, Andrzej
Kucharz, Eugeniusz Józef
Kopeć-Mędrek, Magdalena
Olczyk, Krystyna
description In this study, the effect of 15-month anti-tumor necrosis factor alpha (TNF-α) treatment on circulating levels of plasma sulfated glycosaminoglycans (GAGs) and the nonsulfated GAG hyaluronic acid (HA) in female rheumatoid arthritis (RA) patients was assessed. Plasma was obtained from healthy subjects and RA women treated with TNF-α antagonists (etanercept or adalimumab or certolizumab pegol) in combination with methotrexate. GAGs were isolated from plasma samples using ion exchange low-pressure liquid chromatography. Total sulfated GAGs were quantified using a hexuronic acid assay. Plasma levels of keratan sulfate (KS) and HA were measured using immunoassay kits. Total sulfated GAGs and HA levels were higher in female RA patients before treatment in comparison to healthy subjects. KS levels did not differ between RA women and controls. Anti-TNF-α treatment resulted in normalization of plasma total GAG and HA levels in RA patients, without any effect on KS levels. Our results suggest that anti-TNF-α therapy has a beneficial effect on extracellular matrix remodeling in the course of RA.
doi_str_mv 10.1186/s13075-018-1711-z
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c9ba23ff973b4498a6cb5da2793e566f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c9ba23ff973b4498a6cb5da2793e566f</doaj_id><sourcerecordid>2108777939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-4c9965f93d2627fc2479c7441f5d75868083655f674ea7dd960b2d9aa50f35423</originalsourceid><addsrcrecordid>eNpdkk1uFDEQhVsIRELgAGyQJTZsHNr_7Q0SihISKYJNWFvVbnvGo-72YLsTJbfiIpwJTyZECSuXXO99qiq9pnlP2mNCOvk5E9YqgVvSYaIIwXcvmkPCVYclk_Tlk_qgeZPzpm0p1ZS_bg5YrVTXicNmOfXe2ZJR9AgQEXiKc1kjmEvAV9_P8J_fqCQHZXJzQXFG2xHyBGh01268N63GWxszTGGOuxLmjMKMbmI1oJtQUWntlglKDAOCVNYplJDfNq88jNm9e3iPmp9np1cn5_jyx7eLk6-X2HLNCuZWaym8ZgOVVHlLudJWcU68GJToZNd2TArhpeIO1DBo2fZ00ACi9Uxwyo6aiz13iLAx2xQmSLcmQjD3HzGtTJ0p2NEZq3ugzHutWM-57kDaXgxAlWZOSOkr68uetV36yQ22HiTB-Az6vDOHtVnFayMJF4zpCvj0AEjx1-JyMVPI1o0jzC4u2VBCKKn7clKlH_-TbuKS5nqqqmo7pepUOyDZq2yKOSfnH4chrdkFxOwDYmpAzC4g5q56Pjzd4tHxLxHsL8Tdt_U</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2108777939</pqid></control><display><type>article</type><title>Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Szeremeta, Anna ; Jura-Półtorak, Agnieszka ; Koźma, Ewa Maria ; Głowacki, Andrzej ; Kucharz, Eugeniusz Józef ; Kopeć-Mędrek, Magdalena ; Olczyk, Krystyna</creator><creatorcontrib>Szeremeta, Anna ; Jura-Półtorak, Agnieszka ; Koźma, Ewa Maria ; Głowacki, Andrzej ; Kucharz, Eugeniusz Józef ; Kopeć-Mędrek, Magdalena ; Olczyk, Krystyna</creatorcontrib><description>In this study, the effect of 15-month anti-tumor necrosis factor alpha (TNF-α) treatment on circulating levels of plasma sulfated glycosaminoglycans (GAGs) and the nonsulfated GAG hyaluronic acid (HA) in female rheumatoid arthritis (RA) patients was assessed. Plasma was obtained from healthy subjects and RA women treated with TNF-α antagonists (etanercept or adalimumab or certolizumab pegol) in combination with methotrexate. GAGs were isolated from plasma samples using ion exchange low-pressure liquid chromatography. Total sulfated GAGs were quantified using a hexuronic acid assay. Plasma levels of keratan sulfate (KS) and HA were measured using immunoassay kits. Total sulfated GAGs and HA levels were higher in female RA patients before treatment in comparison to healthy subjects. KS levels did not differ between RA women and controls. Anti-TNF-α treatment resulted in normalization of plasma total GAG and HA levels in RA patients, without any effect on KS levels. Our results suggest that anti-TNF-α therapy has a beneficial effect on extracellular matrix remodeling in the course of RA.</description><identifier>ISSN: 1478-6362</identifier><identifier>ISSN: 1478-6354</identifier><identifier>EISSN: 1478-6362</identifier><identifier>DOI: 10.1186/s13075-018-1711-z</identifier><identifier>PMID: 30227885</identifier><language>eng</language><publisher>England: BioMed Central</publisher><subject><![CDATA[Acids ; Adalimumab - administration & dosage ; Adult ; Antirheumatic Agents - administration & dosage ; Arthritis ; Arthritis, Rheumatoid - blood ; Arthritis, Rheumatoid - drug therapy ; Biomarkers - blood ; Certolizumab Pegol - administration & dosage ; Cytokines ; Diabetes ; Drug Therapy, Combination ; Etanercept - administration & dosage ; Extracellular matrix ; Female ; Glycosaminoglycans ; Glycosaminoglycans - blood ; Health risk assessment ; Humans ; Hyaluronic acid ; Inflammation ; Keratan sulfate ; Metabolism ; Metabolites ; Methotrexate - administration & dosage ; Middle Aged ; Monoclonal antibodies ; Oxidative stress ; Pathogenesis ; Rheumatoid arthritis ; Time Factors ; TNF inhibitors ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Tumor Necrosis Factor-alpha - metabolism ; Tumor necrosis factor-alpha inhibitors ; Tumor necrosis factor-TNF ; Womens health]]></subject><ispartof>Arthritis research &amp; therapy, 2018-09, Vol.20 (1), p.211-211, Article 211</ispartof><rights>Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s). 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-4c9965f93d2627fc2479c7441f5d75868083655f674ea7dd960b2d9aa50f35423</citedby><cites>FETCH-LOGICAL-c493t-4c9965f93d2627fc2479c7441f5d75868083655f674ea7dd960b2d9aa50f35423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145339/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2108777939?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30227885$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Szeremeta, Anna</creatorcontrib><creatorcontrib>Jura-Półtorak, Agnieszka</creatorcontrib><creatorcontrib>Koźma, Ewa Maria</creatorcontrib><creatorcontrib>Głowacki, Andrzej</creatorcontrib><creatorcontrib>Kucharz, Eugeniusz Józef</creatorcontrib><creatorcontrib>Kopeć-Mędrek, Magdalena</creatorcontrib><creatorcontrib>Olczyk, Krystyna</creatorcontrib><title>Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis</title><title>Arthritis research &amp; therapy</title><addtitle>Arthritis Res Ther</addtitle><description>In this study, the effect of 15-month anti-tumor necrosis factor alpha (TNF-α) treatment on circulating levels of plasma sulfated glycosaminoglycans (GAGs) and the nonsulfated GAG hyaluronic acid (HA) in female rheumatoid arthritis (RA) patients was assessed. Plasma was obtained from healthy subjects and RA women treated with TNF-α antagonists (etanercept or adalimumab or certolizumab pegol) in combination with methotrexate. GAGs were isolated from plasma samples using ion exchange low-pressure liquid chromatography. Total sulfated GAGs were quantified using a hexuronic acid assay. Plasma levels of keratan sulfate (KS) and HA were measured using immunoassay kits. Total sulfated GAGs and HA levels were higher in female RA patients before treatment in comparison to healthy subjects. KS levels did not differ between RA women and controls. Anti-TNF-α treatment resulted in normalization of plasma total GAG and HA levels in RA patients, without any effect on KS levels. Our results suggest that anti-TNF-α therapy has a beneficial effect on extracellular matrix remodeling in the course of RA.</description><subject>Acids</subject><subject>Adalimumab - administration &amp; dosage</subject><subject>Adult</subject><subject>Antirheumatic Agents - administration &amp; dosage</subject><subject>Arthritis</subject><subject>Arthritis, Rheumatoid - blood</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Biomarkers - blood</subject><subject>Certolizumab Pegol - administration &amp; dosage</subject><subject>Cytokines</subject><subject>Diabetes</subject><subject>Drug Therapy, Combination</subject><subject>Etanercept - administration &amp; dosage</subject><subject>Extracellular matrix</subject><subject>Female</subject><subject>Glycosaminoglycans</subject><subject>Glycosaminoglycans - blood</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Hyaluronic acid</subject><subject>Inflammation</subject><subject>Keratan sulfate</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Methotrexate - administration &amp; dosage</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Oxidative stress</subject><subject>Pathogenesis</subject><subject>Rheumatoid arthritis</subject><subject>Time Factors</subject><subject>TNF inhibitors</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><subject>Tumor necrosis factor-alpha inhibitors</subject><subject>Tumor necrosis factor-TNF</subject><subject>Womens health</subject><issn>1478-6362</issn><issn>1478-6354</issn><issn>1478-6362</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkk1uFDEQhVsIRELgAGyQJTZsHNr_7Q0SihISKYJNWFvVbnvGo-72YLsTJbfiIpwJTyZECSuXXO99qiq9pnlP2mNCOvk5E9YqgVvSYaIIwXcvmkPCVYclk_Tlk_qgeZPzpm0p1ZS_bg5YrVTXicNmOfXe2ZJR9AgQEXiKc1kjmEvAV9_P8J_fqCQHZXJzQXFG2xHyBGh01268N63GWxszTGGOuxLmjMKMbmI1oJtQUWntlglKDAOCVNYplJDfNq88jNm9e3iPmp9np1cn5_jyx7eLk6-X2HLNCuZWaym8ZgOVVHlLudJWcU68GJToZNd2TArhpeIO1DBo2fZ00ACi9Uxwyo6aiz13iLAx2xQmSLcmQjD3HzGtTJ0p2NEZq3ugzHutWM-57kDaXgxAlWZOSOkr68uetV36yQ22HiTB-Az6vDOHtVnFayMJF4zpCvj0AEjx1-JyMVPI1o0jzC4u2VBCKKn7clKlH_-TbuKS5nqqqmo7pepUOyDZq2yKOSfnH4chrdkFxOwDYmpAzC4g5q56Pjzd4tHxLxHsL8Tdt_U</recordid><startdate>20180918</startdate><enddate>20180918</enddate><creator>Szeremeta, Anna</creator><creator>Jura-Półtorak, Agnieszka</creator><creator>Koźma, Ewa Maria</creator><creator>Głowacki, Andrzej</creator><creator>Kucharz, Eugeniusz Józef</creator><creator>Kopeć-Mędrek, Magdalena</creator><creator>Olczyk, Krystyna</creator><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180918</creationdate><title>Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis</title><author>Szeremeta, Anna ; Jura-Półtorak, Agnieszka ; Koźma, Ewa Maria ; Głowacki, Andrzej ; Kucharz, Eugeniusz Józef ; Kopeć-Mędrek, Magdalena ; Olczyk, Krystyna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-4c9965f93d2627fc2479c7441f5d75868083655f674ea7dd960b2d9aa50f35423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acids</topic><topic>Adalimumab - administration &amp; dosage</topic><topic>Adult</topic><topic>Antirheumatic Agents - administration &amp; dosage</topic><topic>Arthritis</topic><topic>Arthritis, Rheumatoid - blood</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Biomarkers - blood</topic><topic>Certolizumab Pegol - administration &amp; dosage</topic><topic>Cytokines</topic><topic>Diabetes</topic><topic>Drug Therapy, Combination</topic><topic>Etanercept - administration &amp; dosage</topic><topic>Extracellular matrix</topic><topic>Female</topic><topic>Glycosaminoglycans</topic><topic>Glycosaminoglycans - blood</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Hyaluronic acid</topic><topic>Inflammation</topic><topic>Keratan sulfate</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Methotrexate - administration &amp; dosage</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Oxidative stress</topic><topic>Pathogenesis</topic><topic>Rheumatoid arthritis</topic><topic>Time Factors</topic><topic>TNF inhibitors</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><topic>Tumor necrosis factor-alpha inhibitors</topic><topic>Tumor necrosis factor-TNF</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Szeremeta, Anna</creatorcontrib><creatorcontrib>Jura-Półtorak, Agnieszka</creatorcontrib><creatorcontrib>Koźma, Ewa Maria</creatorcontrib><creatorcontrib>Głowacki, Andrzej</creatorcontrib><creatorcontrib>Kucharz, Eugeniusz Józef</creatorcontrib><creatorcontrib>Kopeć-Mędrek, Magdalena</creatorcontrib><creatorcontrib>Olczyk, Krystyna</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Arthritis research &amp; therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Szeremeta, Anna</au><au>Jura-Półtorak, Agnieszka</au><au>Koźma, Ewa Maria</au><au>Głowacki, Andrzej</au><au>Kucharz, Eugeniusz Józef</au><au>Kopeć-Mędrek, Magdalena</au><au>Olczyk, Krystyna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis</atitle><jtitle>Arthritis research &amp; therapy</jtitle><addtitle>Arthritis Res Ther</addtitle><date>2018-09-18</date><risdate>2018</risdate><volume>20</volume><issue>1</issue><spage>211</spage><epage>211</epage><pages>211-211</pages><artnum>211</artnum><issn>1478-6362</issn><issn>1478-6354</issn><eissn>1478-6362</eissn><abstract>In this study, the effect of 15-month anti-tumor necrosis factor alpha (TNF-α) treatment on circulating levels of plasma sulfated glycosaminoglycans (GAGs) and the nonsulfated GAG hyaluronic acid (HA) in female rheumatoid arthritis (RA) patients was assessed. Plasma was obtained from healthy subjects and RA women treated with TNF-α antagonists (etanercept or adalimumab or certolizumab pegol) in combination with methotrexate. GAGs were isolated from plasma samples using ion exchange low-pressure liquid chromatography. Total sulfated GAGs were quantified using a hexuronic acid assay. Plasma levels of keratan sulfate (KS) and HA were measured using immunoassay kits. Total sulfated GAGs and HA levels were higher in female RA patients before treatment in comparison to healthy subjects. KS levels did not differ between RA women and controls. Anti-TNF-α treatment resulted in normalization of plasma total GAG and HA levels in RA patients, without any effect on KS levels. Our results suggest that anti-TNF-α therapy has a beneficial effect on extracellular matrix remodeling in the course of RA.</abstract><cop>England</cop><pub>BioMed Central</pub><pmid>30227885</pmid><doi>10.1186/s13075-018-1711-z</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1478-6362
ispartof Arthritis research & therapy, 2018-09, Vol.20 (1), p.211-211, Article 211
issn 1478-6362
1478-6354
1478-6362
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_c9ba23ff973b4498a6cb5da2793e566f
source Publicly Available Content Database; PubMed Central
subjects Acids
Adalimumab - administration & dosage
Adult
Antirheumatic Agents - administration & dosage
Arthritis
Arthritis, Rheumatoid - blood
Arthritis, Rheumatoid - drug therapy
Biomarkers - blood
Certolizumab Pegol - administration & dosage
Cytokines
Diabetes
Drug Therapy, Combination
Etanercept - administration & dosage
Extracellular matrix
Female
Glycosaminoglycans
Glycosaminoglycans - blood
Health risk assessment
Humans
Hyaluronic acid
Inflammation
Keratan sulfate
Metabolism
Metabolites
Methotrexate - administration & dosage
Middle Aged
Monoclonal antibodies
Oxidative stress
Pathogenesis
Rheumatoid arthritis
Time Factors
TNF inhibitors
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor Necrosis Factor-alpha - metabolism
Tumor necrosis factor-alpha inhibitors
Tumor necrosis factor-TNF
Womens health
title Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T09%3A00%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20a%2015-month%20anti-TNF-%CE%B1%20treatment%20on%20plasma%20levels%20of%20glycosaminoglycans%20in%20women%20with%20rheumatoid%20arthritis&rft.jtitle=Arthritis%20research%20&%20therapy&rft.au=Szeremeta,%20Anna&rft.date=2018-09-18&rft.volume=20&rft.issue=1&rft.spage=211&rft.epage=211&rft.pages=211-211&rft.artnum=211&rft.issn=1478-6362&rft.eissn=1478-6362&rft_id=info:doi/10.1186/s13075-018-1711-z&rft_dat=%3Cproquest_doaj_%3E2108777939%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c493t-4c9965f93d2627fc2479c7441f5d75868083655f674ea7dd960b2d9aa50f35423%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2108777939&rft_id=info:pmid/30227885&rfr_iscdi=true